A docking study was done with specific pharmacological targets, such as the progesterone receptor and the aromatase enzymatic protein of breast cancer, which is implicated in the pathophysiology and induction of cancer, to explain the antioxidant activity of the produced compounds Figure 1. The gene discussed is CYP19A1; the disease is breast cancer.